Chief Executive Officer
Chief Financial Officer
Yossi Gilgun-Sherki, Ph.D.
Executive clinical consultant
Tali Gorfine, M.D.
Executive Clinical Development Consultant
Liat Hayardeny - Brueck, Ph.D.
Chief Scientific Officer
Shaul E. Kadosh
Biostatistical & Clinical Research Consulting
Joseph Kaspi, Ph.D.
Senior CMC Director
Dalia Medini, Ph.D.
Guy Nehemya, Adv.
Chief Operating Officer
Clinical Pharmacology Specialist
Doron Shinar, Ph.D.
Yohai Stenzler, CPA
Chief Accounting Officer
Mr. Baharaff is the co-founder of Galmed and has served as CEO since 2012 and President as of 2015. Mr. Baharaff holds a Bachelor of Science degree from the London School of Economics University of London and LLB and M.A. degrees from Cambridge University.
+25 years of experience in the global financial markets, including significant experience on the buy-side of life sciences companies.
Since 2016, Mr. Cohen has served as Chief Executive Officer at Tangram Strategic Ltd. Tangram Strategic is a financial solutions company that provides research and consulting services to Hedge Funds, Family Offices, FinTech, and other Financial Institutions. Tangram also manages outsourced CFO responsibilities.
Prior to that, Doron was the Head of Research at Gems Investments Research in Tel Aviv, Israel. There he provided research to Fund of Funds that specialize in Hedge Funds. During his time, he managed three teams of analysts in Investment Research, Operations Research, and Risk Analysis.
Mr. Cohen holds a Master of Science degree in management from Boston University and a Bachelor’s degree in philosophy and political science from the University of New South Wales.
+24 years of experience in academic research & the pharmaceutical/ medical device industry. Holds a Ph.D. in Neuroscience and MBA in Health Innovation. An executive scientific, clinical and strategic drug development consultant. Prior to joining Galmed,worked as Global Clinical Program Leader & Senior Clinical Scientist at Teva Pharmaceuticals.
+ 13 years of clinical and medical experience . Holds an MD. and a Ph.D. degrees in the field of functional magnetic resonance imaging (fMRI) from Tel-Aviv University. Prior to joining Galmed, she served as a Senior Clinical Program Leader at Teva Pharmaceuticals
+21 years experience in drug development. Holds Ph.D. in Life Sciences, Immune Systems, Autoimmune Diseases, and MBA in Organizational Behaviour. Prior to joining Galmed, worked as Senior Global Scientific Director at Teva Pharmaceuticals.
During the 24-year career at Teva Pharmaceutical Industries Ltd, Shaul served as the Global Innovative R&D management team member heading the division's professional units and oversaw all biostatistical aspects of the successful global submissions of Copaxone for multiple sclerosis and rasagiline for Parkinson's disease. Shaul has received the Rothschild Prize for industrial innovation twice; for the development of Copaxone and alpha D3.
+40 years of experience in the development of chemical processes for APIs. Formerly worked as V.P. for R&D and Chief Scientific Officer in Perrigo API.
+30 years of industry experience. Prior to joining Galmed, worked as analytical team leader and CMC forum leader at the R&D division in Teva Pharmaceutical.
Holds an MBA from the Arison School of Business at IDC Herzliya and an LL.B. from the College of Management and has been a member of the Israeli Bar Association since 2012.
+30 years of experience in the Pharma Industry. Holds B.S.c (Hons) and a P.h.D in pharmacology at King's College London and MBBS at King's College Hospital (KCH)
+30 years of industry experience. American Board Certified Toxicologist and Consultant for Preclinical Drug Development. Prior to joining Galmed, worked as Head of Toxicology and Preclinical Development at the Innovative R&D of Teva Pharmaceuticals.
+12 years of experience in financing, taxes, auditing, and accounting of public and private companies,. Holds an MBA degree in Finance from Recanati Business School at Tel Aviv University and a B.A. in Economics and Accounting from Ben-Gurion University. Prior to joining Galmed, worked as Audit Manager at EY.
David Sidransky, M.D.
Lead Independent Director
President & CEO
Carol L. Brosgart, M.D.
Dr. David Sidransky, has served as a member of Galmed’s board of directors since 2014. Dr. Sidransky is a renowned oncologist and research scientist who was profiled by TIME magazine in 2001 as one of the top physicians and scientists in America. He is widely recognized for his work with early detection of cancer. Dr. Sidransky serves as the Director of the Head and Neck Cancer Research Program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, and is a Professor of Oncology, Otolaryngology, Cellular & Molecular Medicine, Urology, Genetics, and Pathology at John Hopkins University and Hospital.
He has authored more than 600 peer-reviewed publications, and has contributed to more than 60 cancer reviews and chapters. Dr. Sidransky is a founder of a number of biotechnology companies and holds numerous biotechnology patents. He has been the recipient of numerous awards and honors, including the 1997 Sarstedt International Prize from the German Society of Clinical Chemistry, the 1998 Alton Ochsner Award Relating Smoking and Health by the American College of Chest Physicians, and the 2004 Hinda Rosenthal Award and 2017 Team Award presented by the American Association of Cancer Research. Dr. Sidransky previously served as Vice Chairman of the Board of Directors of ImClone.
He is Chairman of the Board of Advaxis Inc, Lead Director at Champions Oncology, and on the Board of Directors of Orgenesis, Ayala Pharma and Ascentage Pharma. He is a current and previous member of scientific advisory boards of corporations and institutions, including Amgen, MedImmune, Roche and Veridex, LLC (a Johnson & Johnson diagnostic company), among others. In addition, Dr. Sidransky served as Director of The American Association for Cancer Research from 2005 to 2008. He received his B.A. from Brandeis University and his M.D. from the Baylor College of Medicine.
Mr. Baharaff is the co-founder of Galmed, and has served as CEO since 2012, and President as of 2015. Previously, he held a number of senior executive positions, including SVP at Isramex Projects Ltd., and Managing Director of T+M Trusteeship & Management. He also served as a Director of the Tel-Aviv Museum of Arts and Chair of the Board's Education Committee from 2000 to 2018 and received the Tel-Aviv Museum Honorary Fellowship for his educational activities. He currently serves as a Director at The Rubin Museum.
Mr. Baharaff holds a Bachelor of Science degree from the London School of Economics and LLB and MA degrees from Cambridge University. Mr. Baharaff is also a member of the Israel Bar Association Since 1993.
Dr. Brosgart has served as a member of Galmed’s Board of Directors since 2017. Dr. Brosgart served as a member of Tobira Therapeutics’s Board of Directors from 2009 until it was acquired by Allergan in 2016 and on the Board of Juvaris, a vaccine company, until it’s assets were outlicensed to Bayer and Colby.Since January 2018, she has served on the Board of Directors of Abivax, a biotechnology company, headquartered in Paris, working on ulcerative colitis and other inflammatory diseases. She also is a member of the Board of Enochian BioSciences, a company focused on HIV Cure, HBV Cure, and COVID-19. And, she is a member of the Board of Directors of Intrivo Diagnostics, a distributor of COVID-19 diagnostic tests developed by Access Bio (PCR, Antigen, and Antibody). Dr. Brosgart serves as a consultant to Dynavax, Allergan, Moderna and a number of biotechnology companies in the areas of liver disease and infectious diseases. Dr. Brosgart currently serves on the Executive Committee of the Forum for Collaborative Research, the Steering Committee of the HBV Cure Group at the Forum, and is on the Board of Directors of the Hepatitis B Foundation, the Northern California American Liver Foundation ,and the Board of Berkeley Community Scholars. She is active in the public policy arena for AASLD and IDSA/HIVMA.
Dr. Brosgart served as Senior Advisor on Science and Policy to the Division of Viral Hepatitis at the CDC and to the Viral Hepatitis Action Coalition at the CDC Foundation from 2011 to 2013. Dr. Brosgart has also served as a member of the clinical faculty of the School of Medicine at the University of California, San Francisco for the past four decades, where she is a Clinical Professor of Medicine, Biostatistics and Epidemiology in the Division of Global Health and Infectious Diseases. In 2011 Dr. Brosgart served as Chief Medical Officer at biotechnology company Alios BioPharma, Inc. Prior to Alios, Dr. Brosgart served as Senior Vice President and Chief Medical Officer of Children’s Hospital & Research Center in Oakland, California, from 2009 until February 2011.
Previously, she served for eleven years, from 1998 until 2009, at the biopharmaceutical company Gilead Sciences, Inc., where she held a number of senior management roles, most recently as Vice President, Public Health and Policy and earlier as Vice President, Clinical Research and Vice President, Medical Affairs and Global Medical Director, Hepatitis. She led the clinical development of a number of agents at Gilead, including Viread and Hepsera. Prior to Gilead, Dr. Brosgart worked for more than 20 years in clinical care, research and teaching at several Bay Area medical centers. She was the founder and Medical Director of the East Bay AIDS Center at Alta Bates Medical Center in Berkeley, California, from 1987 until 1998 and served as the Medical Director of Central Health Center, Oakland, California, of the Alameda County Health Care Services Agency from 1978 until 1987.
Dr. Brosgart has also served on the boards of privately held companies and public, not-for-profit domestic and global health organizations. Dr. Brosgart received a B.S. in Community Medicine from the University of California, Berkeley and received an M.D. from the University of California, San Francisco. Her residency training was in pediatrics, public health and preventive medicine at UCSF and UC Berkeley School of Public Health. She has published extensively in the areas of HIV, HBV, CMV, and liver disease.
Shmuel Nir, has served as a member of Galmed’s board of directors since 2007. Mr. Nir serves as President and Chief Executive Officer of Tushia Consulting Engineers Ltd..From January 2001 TO January 2016, Mr. Nir served as Chairman of the Board of Directors of Matan Digital Printers Ltd. From 1998 to 2008, he served as President and Chief Executive Officer of Macpell Industries Ltd.
Between 1991 and 1998, Mr. Nir was Executive Vice President of Operations at Macpell Industries Ltd. and President and Chief Executive Officer of two of its subsidiaries: New Net Industries Ltd., and New Net Assets Ltd. Prior to 1991, Mr. Nir held management positions with Intel Corporation in Jerusalem, Israel and Tefen Management Consulting. Between 1999 and 2006, Mr. Nir served as Managing Partner at Spring Venture Capital Fund. He earned a B.Sc. in Industrial Engineering and Management from the Technion — Israel Institute of Technology in Haifa in 1989.
Joined the Board in June 2020.Amir Poshinski is an entrepreneur with over 20 years’ management and leadership experience across multiple industries, including technology, biotechnology, banking and real estate. Mr. Poshinski is the owner of DAP Holdings where since 2010 he acts as a management consultant and strategic advisor to global companies. Mr. Poshinski serves as member of Michman Financing’s (TLV: MCMN) Board of Directors and on the advisory board of Benson Oak Ventures, a venture focused fund, as well as several other private companies. Prior to 2010, Mr. Poshinski served as Deputy CEO of Primsa Investment House, which at the time was Israel’s largest investment house, Deputy CEO of Discount Mortgage Bank, the real estate lending arm of one of Israel’s largest banks, VP of Marketing of Comverse, a telecommunications software company that was listed on Nasdaq, VP Marketing, Sales and Advertising of MifalHapayis, Israel’s national lottery, and VP and Deputy CEO of the Economic Company of the Local Authorities Association. Mr. Poshinski previously served on the boards of TAS-AGT (a TATA joint venture), Excellence Nessuah Mutual Funds, and Therapix Biosciences as well as several other private companies. Mr. Poshinski holds a B.A. in Business Administration and Marketing from the New York Institute of Technology.
Prof. Arun Sanyal, MD
Professor of Medicine and Chairman of the Gastroenterology Division of Virginia Commonwealth University (VCU) Medical Center in Richmond, Virginia.
Prof. Vlad Ratziu, MD
Professor of Hepatology at the Université Pierre et Marie Curie and the Hôpital Pitié-Salpêtrière Medical School in Paris, France.
Prof. Scott Friedman, MD
Dean for Therapeutic Discovery and Chief of the Division of Liver Diseases, at Icahn School of Medicine at Mount Sinai in New York, NY.
José María Mato
General Director of the Centers for Cooperative Research in Biosciences Biogune (Bilbao) and Biomagune (San Sebastián), and Research Professor of the Spanish National Research Council, Spain.
Prof. Rohit Loomba, MD
Professor of Medicine and Vice Chief, Division of Gastroenterology Adjunct Professor, Epidemiology & Public Health, University of California, San Diego, CA.
Prof. Ran Oren, MD
Previously headed the Institute of Gastroenterology and Liver Diseases at Hadassah Ein Kerem Hospital, Jerusalem, Israel